These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 25651256)

  • 1. Shorter moxifloxacin-based regimens for drug-sensitive tuberculosis.
    Gillespie SH; Mendel CM;
    N Engl J Med; 2015 Feb; 372(6):577. PubMed ID: 25651256
    [No Abstract]   [Full Text] [Related]  

  • 2. Shorter moxifloxacin-based regimens for drug-sensitive tuberculosis.
    Alffenaar JW; Gumbo T; Aarnoutse R
    N Engl J Med; 2015 Feb; 372(6):576. PubMed ID: 25651257
    [No Abstract]   [Full Text] [Related]  

  • 3. Shorter moxifloxacin-based regimens for drug-sensitive tuberculosis.
    Sellier PO; Clevenbergh P; Bergmann JF
    N Engl J Med; 2015 Feb; 372(6):577. PubMed ID: 25651258
    [No Abstract]   [Full Text] [Related]  

  • 4. Four-month fluoroquinolone-containing regimens are inferior to standard 6-month tuberculosis treatment.
    Sterling TR
    Evid Based Med; 2015 Aug; 20(4):128-9. PubMed ID: 25926523
    [No Abstract]   [Full Text] [Related]  

  • 5. Shortening treatment for tuberculosis--to basics.
    Warner DF; Mizrahi V
    N Engl J Med; 2014 Oct; 371(17):1642-3. PubMed ID: 25337754
    [No Abstract]   [Full Text] [Related]  

  • 6. New effective antituberculosis regimens.
    Sotgiu G; Migliori GB
    Lancet; 2015 May; 385(9979):1703-1704. PubMed ID: 25795077
    [No Abstract]   [Full Text] [Related]  

  • 7. [Respiratory fluoroquinolones and pulmonary tuberculosis treatment when the main drugs are ineffective].
    Lazareva NB; Khaĭmenova TIu; Khaĭmenov AIa
    Antibiot Khimioter; 2008; 53(5-6):14-20. PubMed ID: 19069177
    [No Abstract]   [Full Text] [Related]  

  • 8. Moxifloxacin plus standard first-line therapy in the treatment of pulmonary tuberculosis: A meta-analysis.
    Chen Z; Liang JQ; Wang JH; Feng SS; Zhang GY
    Tuberculosis (Edinb); 2015 Jul; 95(4):490-6. PubMed ID: 25964137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Sparfloxacin in combined therapy for pulmonary tuberculosis].
    Sokolova GB; Khaĭmenova TIu; Lazareva IaV; Khaĭmenov AIa
    Antibiot Khimioter; 2008; 53(5-6):21-7. PubMed ID: 19069178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should moxifloxacin be substituted for isoniazid as a first-line antituberculosis drug?
    Mohapatra PR
    Am J Respir Crit Care Med; 2009 Oct; 180(7):686; author reply 686-7. PubMed ID: 19762595
    [No Abstract]   [Full Text] [Related]  

  • 11. [Floracide, a Russian 3rd generation fluoroquinolone in complex therapy of tuberculosis].
    Sokolova GB; Kirtaeva OV; Lazareva IaV; Tsybanev AA
    Antibiot Khimioter; 2008; 53(5-6):28-31. PubMed ID: 19069179
    [No Abstract]   [Full Text] [Related]  

  • 12. Fluoroquinolones for treating tuberculosis.
    Ziganshina LE; Squire SB
    Cochrane Database Syst Rev; 2008 Jan; (1):CD004795. PubMed ID: 18254061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluoroquinolones for the treatment of pulmonary tuberculosis.
    Moadebi S; Harder CK; Fitzgerald MJ; Elwood KR; Marra F
    Drugs; 2007; 67(14):2077-99. PubMed ID: 17883288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
    Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
    Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Synthesis and tuberculostatic activity of fluoridized 3-Z-hydrazine-2-benzoyl acrylates and their cyclization products].
    Kravcheko MA; Nosova EV; Lipunova GN; Chasovskikh OM; Sokolov VA; Charushin VN
    Probl Tuberk Bolezn Legk; 2003; (7):49-52. PubMed ID: 12939881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How are we creating fluoroquinolone-resistant tuberculosis?
    Bernardo J; Yew WW
    Am J Respir Crit Care Med; 2009 Aug; 180(4):288-9. PubMed ID: 19661251
    [No Abstract]   [Full Text] [Related]  

  • 17. Sputum culture conversion with moxifloxacin-containing regimens in the treatment of patients with newly diagnosed sputum-positive pulmonary tuberculosis in South India.
    Velayutham BV; Allaudeen IS; Sivaramakrishnan GN; Perumal V; Nair D; Chinnaiyan P; Paramasivam PK; Dhanaraj B; Santhanakrishnan RK; Navaneethapandian GP; Marimuthu MK; Kumar V; Kandasamy C; Dharuman K; Elangovan T; Narasimhan M; Rathinam S; Vadivelu G; Rathinam P; Chockalingam C; Jayabal L; Swaminathan S; Shaheed JM
    Clin Infect Dis; 2014 Nov; 59(10):e142-9. PubMed ID: 25028463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial.
    Diacon AH; Dawson R; von Groote-Bidlingmaier F; Symons G; Venter A; Donald PR; van Niekerk C; Everitt D; Winter H; Becker P; Mendel CM; Spigelman MK
    Lancet; 2012 Sep; 380(9846):986-93. PubMed ID: 22828481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment Outcomes with Fluoroquinolone-Containing Regimens for Isoniazid-Resistant Pulmonary Tuberculosis.
    Lee H; Jeong BH; Park HY; Jeon K; Huh HJ; Lee NY; Koh WJ
    Antimicrob Agents Chemother; 2016 Jan; 60(1):471-7. PubMed ID: 26525801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Fluoroquinolones in the Treatment of Tuberculosis in 2019.
    Pranger AD; van der Werf TS; Kosterink JGW; Alffenaar JWC
    Drugs; 2019 Feb; 79(2):161-171. PubMed ID: 30617959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.